^ Back to Top


Long COVID: an evolving enigma

Preventing SARS-CoV-2 infection and managing the acute phase of illness has been the central focus of the New Zealand healthcare... View Article

June 2023

MMR vaccination remains a priority

Measles, mumps and rubella are vaccine-preventable causes of significant morbidity and mortality (particularly for measles), that... View Article

December 2021

HIV Pre-Exposure Prophylaxis (PrEP): a how-to guide

Human Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis (PrEP) is a daily oral tablet that, when taken as prescribed, can... View Article

April 2019

HPV vaccination: getting the programme back on track

Vaccination against human papillomavirus (HPV) infection provides safe and effective protection from genital warts, most cervical... View Article

March 2019

Hepatitis C management in primary care has changed

A new direct-acting antiviral (DAA) oral regimen for the treatment of hepatitis C, glecaprevir + pibrentasvir (Maviret) will be... View Article

January 2019

Testing for hepatitis C virus (HCV) in patients at high risk of infection

Hepatitis C infection occurs through exposure to infected blood or body fluids. The majority of newly acquired infections in New... View Article

January 2019

Pre-treatment assessment for patients with chronic HCV infection

Patients should be assessed for cirrhosis via clinical examination, laboratory tests and an APRI score (or liver elastography... View Article

January 2019

Management and follow-up of patients prescribed glecaprevir + pibrentasvir

Glecaprevir + pibrentasvir is taken once daily for eight weeks. Headache and fatigue are the most likely adverse effects. HCV... View Article

January 2019

Hepatitis C is now curable:
contributed by Dr Tony Farrell

Dr Tony Farrell is a general practitioner in Mount Maunganui and has a Fellowship in Addiction Medicine. He has a special interest... View Article

January 2019

Hepatitis B: treatments now available for primary care

Tenofovir disoproxil and entecavir are once daily oral antiviral medicines, recommended as first-line treatments for patients... View Article

August 2018

News item: Discussion on Zostavax

Since publication of our article on Zostavax vaccine in March, 2018, we have received feedback from several readers seeking clarification... View Article

April 2018

Seasonal influenza vaccination: update for 2018

Two subsidised seasonal influenza vaccines, Influvac Tetra (for adults and children aged three years and over) and Fluarix Tetra... View Article

March 2018

Zostavax vaccine: now fully subsidised

Zostavax is a herpes zoster (shingles) vaccine that will become fully subsidised from 1 April, 2018 for people aged 65 years.... View Article

March 2018

Treatment of hepatitis C (HCV) has changed

Three new oral medicine regimens for the treatment of hepatitis C, known as directly acting antivirals (DAAs), are fully subsidised... View Article

September 2016

Valaciclovir – a first line antiviral medicine

Valaciclovir is an antiviral medicine which can be used for the treatment of Herpes simplex infections and herpes zoster. As of... View Article

March 2016